The pill contains lycopene, a natural antioxidant that also gives tomatoes their colour. Experts have suspected for some time that lycopene might be good for avoiding illnesses, including certain cancers and cardiovascular disease. There is some evidence that eating a Mediterranean-style diet, which is rich in tomatoes (as well as other fruit and vegetables and olive oil), is beneficial for health.
A company called CamNutra has come up with its own "tomato pill".
Working independently of CamNutra, and instead funded by the Wellcome Trust, the British Heart Foundation and the National Institute of Health Research, a team at Cambridge University set out to see if this pill would have the desired effect.
They recruited 36 volunteers known to have heart disease and 36 "healthy" controls, who were all given a daily tablet to take, which was either the tomato pill or a placebo. To ensure a fairer trial, neither the volunteers nor the researchers were told what the tablets actually contained until after the two-month study had ended and the results were in.
For comparison, the researchers measured something called forearm blood flow, which is predictive of future cardiovascular risk because narrowed blood vessels can lead to heart attack and stroke.
In the heart disease patients, the tomato pill improved forearm blood flow significantly, while the placebo did not. The supplement had no effect on blood pressure, arterial stiffness or levels of fats in the blood, however.
- A natural antioxidant - substances thought to protect the body's cells from damage
- Found in tomatoes, but also in apricots, watermelon and papaya as well as pink grapefruit
- Lycopene content varies according to the variety of tomato and how it is prepared eg. puree, ketchup, cooked or raw
- It is unclear whether supplements would ever be able to replace the benefits of a varied diet
"However, we cannot answer if this may reduce heart disease - this would need much larger trials to investigate outcomes more carefully."
Prof Jeremy Pearson of the British Heart Foundation said big studies were needed to see if this could become a viable option for patients.
Source: bbc.com